Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Conditioning unit raises quality of lubrication oil

Plug-and-play unit cools and filters lubricant as it circulates, which helps to extend machine service life and cut the need for maintenanceGothenburg, Sweden 25 August 2021: SKF’s Oil Conditioning Unit (OCU) helps to prolong bearing lifetimes by improving the performance of lubricants in service. The plug-and-play unit cools and filters lubrication oil as it circulates. Cooling helps to improve lubricant performance, while filtration removes contaminants. Filtration levels can be selected from coarse to ultra-fine. “All this helps to reduce bearing failures and ensure reliable

Lipum participate at the LSX Nordic Congress

News: Umeå, 25 august, 2021.Lipums CEO Einar Pontén will present Lipum at LSX Nordic Virtual Congress  6-17 September. The LSX Nordic Congress is annual investment and partnering conference for the Nordic life science and healthcare industry.   For further information, please contact:  Einar Pontén, CEOE-post: einar.ponten@lipum.seMobil: +46 70 578 34 95Web: www.lipum.se   About LipumLipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic

Interim report January – June 2021

Strong growth and high rate of acquisitionApril – June 2021 · Net sales increased by 33.9 percent to SEK 2,311 (1,725) million. Organic growth, adjusted for currency effects, was 12.0 (2.3) percent. · EBIT increased to SEK 197 (154) million, which corresponds to an EBIT margin of 8.5 (8.9) percent. · Cash flow from operating activities for the period was SEK 104 (190) million. · Ten acquisitions were made during the quarter, which, on an annual basis, contribute an estimated total sales of SEK 318 million. · Earnings per share for the period amounted to SEK 2.90 (2.38).

Nederman Holding AB resolves to distribute dividends at Extraordinary General Meeting

An Extraordinary General Meeting of Nederman Holding AB (publ) took place on 25 August 2021. The meeting was held only through postal voting, without the possibility to attend in person, in accordance with temporary legislation. In accordance with the Board of Directors’ proposal, the General Meeting resolved to pay a dividend of SEK 1 per share, amounting to SEK 35 093 096 in total. The record date determined for the dividend is Friday 27 August 2021 after which the dividend is expected to be distributed by Euroclear Sweden AB starting on Wednesday, 1 September 2021. For further

Cell Impact reports second quarter results for 2021: Strong growth

Cell Impact AB (Nasdaq First North GM: CI B) reports the following financial summary for the first quarter.· Total revenues for the second quarter amounted to SEK 17.8 million (4.8), which is growth of 270% for the quarter. · Operating result was SEK -23.5 million (-13.3). · The Group's result after financial items was SEK -23.8 million (-13.8). · Earnings per share attributable to the shareholders of the Parent Company totaled SEK -0.41 (-0.30). · Equity was SEK 163.9 million (58.4) or SEK 2.79 per share (1.13) as at the balance sheet date. · Debt/equity ratio was 75% (73%)

Trelleborg publishes Green Finance Framework

Trelleborg Group is publishing a Green Finance Framework today. This will enable the Group to issue green bonds under its existing Medium Term Note (MTN) Program. The green bonds will be used to finance projects that continue to support and develop the Group’s ongoing and future energy efficiency initiatives in production and administration. The framework also empowers Trelleborg’s financing activities to become more involved in the Group’s ‘50 by 25’ climate target, whereby the Group will reduce its CO₂ emissions by 50 percent relative to sales by 2025, combined with its vision of net zero

BioStock: Ultimovacs strengthens clinical validation of UV1 in Q2

Q2 was all about increasing momentum in the clinic for Norwegian Ultimovacs. The company’s universal cancer vaccine UV1 has progressed steadily in one of its phase I trials and in its four phase II trials. CEO Carlos de Sousa joined BioStock for a comment on the newly released report.Read the interview with Carlos de Sousa at biostock.se: https://www.biostock.se/en/2021/08/ultimovacs-strengthens-clinical-validation-of-uv1-in-q2/ This is a press release from BioStock - Connecting Innovation & Capital.

Bricknode accelerates international expansion with key hires in the UK

Bricknode today announced the appointment of two UK hires to support international expansion and increasing demand for its cloud banking solutions. Joel Cope joins the Swedish-based fintech company as Head of Marketing and Barry White has been appointed as Sales Manager.Joel Cope, who joins the company as Head of Marketing, will be responsible for expanding Bricknode’s brand presence and market opportunity. Cope brings a wealth of marketing experience having contributed to several rapid-growth companies in the financial services and fintech industries including Thomson Reuters, Moody’s

Invitation to Clas Ohlson’s Q1 presentation on 8 September

Clas Ohlson will publish the interim report for the first quarter 2021/22 on 8 September at 7:00 a.m. CET. A webcasted presentation of the report will be held at 9:00 a.m. CET the same day.Clas Ohlson invites investors, financial analysts and the media to a webcasted presentation of the interim report for the first quarter 2021/22 on Wednesday 8 September at 9:00 a.m. CET where President and CEO Kristofer Tonström and CFO Pär Christiansen will comment on the report. The interim report for the period May to July 2021/22 will be published at 7:00 a.m. CET and the report and presentation

Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing

York, UK and Uppsala, Sweden (August 25, 2021) Aptamer Group Ltd , the developer of custom affinity tools to enable the life science industry through its proprietary Optimer platform, and Bio-Works Technologies AB , the developer and manufacturer of leading-edge agarose-based purification technologies, today announce that they have entered into an agreement to co-develop a new affinity resin for improved purification and scale up of gene therapy vectors.  Under the agreement, Aptamer Group will develop an Optimer™ ligand capable of

Frontline Colombian team fights COVID-19 with ECMO therapy

Extracorporeal Membrane Oxygenation (ECMO) – providing the body with oxygen when the lungs fail to perform this task – is one of the key pillars in the treatment of severely ill COVID-19 patients. Combined with the professional expertise of the Colombian thoracic surgeon Diego Pardo, it has been an important tool in his efforts to save lives across the region.   As president of the Colombian Association of Thoracic Surgery, Dr. Pardo, also a licensed physician, is one of the country's leading authorities in the area and a pioneer in using ECMO therapy, which is used to keep

Valmet to invest in a new service center in Guangxi, China

Valmet Oyj’s press release on August 25, 2021 at 11:00 a.m. EETValmet will build its fourth service center in China, in the city of Beihai, to further develop its local presence in the fast-growing pulp and paper industry in the Guangxi province. Valmet's new Guangxi Service Center will be in operation by the fourth quarter in 2023. Valmet’s new service center will serve pulp, board, paper and tissue customers close by with main focus on roll maintenance, fiber equipment services and field services including shutdown planning management.   “Guangxi Zhuang Autonomous Region is a fast-

SynAct strengthens IP portfolio – Grant of key European patent covering AP1189

SynAct Pharma AB ("SynAct") today announced that a European patent was granted covering the company’s leading drug candidate AP1189 in methods of treating kidney diseases.SynAct has received information that its European patent EP 3 743 064 B1 was granted on 11 August 2021. The European patent provides exclusivity on the medical use of AP1189 and similar compounds in treating kidney disease, specifically primary nephrotic syndrome, and including membranous nephropathy which is currently being tested in clinical trials. The European patent will now be validated in selected European

Invitation to SAS’ Q3 2021 teleconference

SAS will publish the interim report for the third quarter of the fiscal year 2021 on Wednesday, 1[st] of September 2021, at approximately 08.00 AM (CET). A teleconference and webcast for investors, analysts and media will be held at 10.00 AM (CET). Anko van der Werff, President & CEO and Magnus Örnberg, Executive Vice President & CFO will present and comment the report. The presentation will be held in English via telephone or https://www.sasgroup.net No advance notification is necessary. Dial-in details for the conference call: DK: +45 354 455 77FI: +358 981 710 310NO:

SSG – Disclosure of large shareholding

Reference is made to the stock exchange notification on 24 August 2021 from Self Storage Group ASA (the “Company”) regarding a private placement of NOK 10,350,000 new shares (the "New Shares") in the Company (the “Private Placement”) at a subscription price of NOK 29 per share. Centerbridge Partners L.P has been allocated 3,620,000 new shares in the Private Placement. After completion of the Private Placement, Centerbridge Partners L.P will hold 24,557,078 shares in the Company, which, after issue and registration of the New Shares, will represent approximately 25.94% of the total issued

TOMRA: Mandatory notification of trade

Harald Henriksen, Executive Vice President, Head of TOMRA Collection Solutions and primary insider of TOMRA Systems ASA, has today sold 14,000 shares in TOMRA Systems ASA at a price of NOK 510.00 per share. After the transaction Harald Henriksen holds 41,052 shares in TOMRA Systems ASA.   This information is subject to the disclosure requirements in Regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Financial report for the period January 1 2021 – June 30 2021

Company Announcement No. 9-2021 OrderYOYO A/SInside Information   Copenhagen, August 25, 2021Financial Highlights – strong net revenue growth of 82% H1 2021 vs H1 2020 · Strong net revenue growth H1 2021 vs H1 2020 of 82% - to DKK 53.6m in H1 2021 · Strong ARR growth based in June 2021 compared to June 2020 of 31% - to DKK 105.4m · Solid GMV growth H1 2021 vs H1 2020 of 37% - to DKK 606m · GMV June 2021 as expected – June 2021 was the first month where Covid restrictions were lifted in all our markets which as expected meant a minor slowdown in the growth in take-

Invitation to presentation of Sectra’s three-month interim report 2021/2022

Linköping – August 25, 2021 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) invites analysts, investors, and the media to a presentation of the company’s three-month report with President Torbjörn Kronander and CFO Mats Franzén.Publication of the interim report: 8:15 a.m. (CEST) on September 3, 2021Report presentation: 10:00 a.m. (CEST) on the same date To participate, follow the instructions on Sectra’s website investor.sectra.com/q12122 . The broadcast

Anifera receives further investment from Stonehaven Incubate to initiate additional studies of adjunct therapy in bovine mastitis

· Bovine mastitis is a major economic and welfare challenge for the global dairy industry, reducing both milk yield and quality · Anifera’s unique mode of action aims to improve antibiotic efficacy and ultimately reduce the overall use of antibiotics in multiple disease statesLondon, UK, 25 August 2021 – Anifera, a company focused on developing adjunct therapy to improve the efficacy of antibiotics used in animal health, today announced that it plans to conduct additional studies to explore the impact and effectiveness of adjunct therapy in bovine mastitis, a significant economic and

Launch of Pay by 24SevenOffice

24SevenOffice is pleased to announce the re-launch of the digital payment technology (previously called OptinPay) acquired from Optin Bank ASA. The digital payment solution has been named Pay by 24SevenOffice and is now in production. Since the acquisition of the technology 24SevenOffice has successfully managed to transfer the comprehensive technology platform, including taking over the hosting, re-negotiated necessary agreements and adapting the platform to the new situation.The first version of the payment solution includes flexible payment options through SMS, with card payment, mobile

NENT Group orders ‘Ida Takes Charge’ as latest Viaplay Original

· Series based on Kjersti Halvorsen’s acclaimed debut novel · ‘Ida Takes Charge’ stars Elli Rhiannon Müller Osborne (‘Psychobitch’; ‘Utøya: July 22’) and is directed by Student Academy Award winner Rikke Gregersen · NENT Group to premiere at least 50 original productions in 2021 ‘Ida Takes Charge’, a darkly humorous Norwegian drama series based on the critically acclaimed debut by young novelist Kjersti Halvorsen and directed by rising star Rikke Gregersen, will be the next Viaplay Original from Nordic Entertainment Group (NENT Group). The eight-part series stars Elli Rhiannon

There are no items matching the current filter
There are no more items matching the current filter
Back to top